Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Published by: Global Markets Direct

Published: Sep. 30, 2008 - 145 Pages

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Definitions

2.2.1 Drug delivery devices

2.2.1.1 Needle-free Injections

2.2.1.2 Inhalation Systems

2.2.1.3 Infusion Systems

3 Healthcare Sector Review

3.1 Healthcare Expenditure

3.2 Healthcare Infrastructure

3.3 Healthcare Policy

3.3.1 Health Insurance Act

3.3.2 Healthcare Allowance Act

3.3.3 The Exceptional Medical Expenses Act

4 Drug Delivery Devices in Netherlands

4.1 Drug Delivery Devices Overall Revenues (2000-2012)

4.2 Drug Delivery Devices Overall Volume (2000-2012)

4.3 Drug Delivery Devices Company Shares (2005-2006)

5 Inhalation Systems in Netherlands

5.1 Inhalation Systems Overall Revenues (2000-2012)

5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)

5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)

5.2 Inhalation Systems Overall Volume (2000-2012)

5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)

5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)

5.3 Inhalation Systems Average Price (2000-2012)

5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)

5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)

5.4 Inhalation Systems Distribution Share (2005-2006)

5.5 Inhalation Systems Company Share (2005-2006)

6 Infusion Systems in Netherlands

6.1 Infusion Systems Overall Revenues (2000-2012)

6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)

6.1.2 Syringe Pumps Overall Revenue (2000-2012)

6.1.3 Infusion Pumps Overall Revenues (2000-2012)

6.2 Infusion Systems Overall Volume (2000-2012)

6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)

6.2.2 Syringe Pumps Overall Volume (2000-2012)

6.2.3 Infusion Pumps Overall Volume (2000-2012)

6.3 Infusion Systems Average Price (2000-2012)

6.3.1 Infusion Pumps Average Price (2000-2012)

6.3.2 Syringe Pumps Average Price (2000-2012)

6.3.3 Infusion Disposable Sets Average Price (2000-2012)

6.4 Infusion Systems Distribution Share (2005-2006)

6.5 Infusion Systems Company Share (2005-2006)

7 AstraZeneca PLC Company Profile

7.1 Company Overview

7.2 Business Overview

7.2.1 Products

7.2.2 History

7.3 Locations And Subsidiaries

8 3M Company Profile

8.1 Company Overview

8.2 Business Overview

8.2.1 Consumer and Office

8.2.1.1 Overview

8.2.1.2 Capital Expenditure

8.2.1.3 Market View

8.2.1.4 Key Strategies

8.2.2 Display and Graphics

8.2.2.1 Overview

8.2.2.2 Financials

8.2.2.3 Capital Expenditure

8.2.2.4 Market View

8.2.2.5 Key Strategies

8.2.3 Electro and Communications

8.2.3.1 Overview

8.2.3.2 Financials

8.2.3.3 Capital Expenditure

8.2.3.4 Market View

8.2.3.5 Key Strategies

8.2.4 Health Care

8.2.4.1 Overview

8.2.4.2 Financials

8.2.4.3 Capital Expenditure

8.2.4.4 Market View

8.2.4.5 Key Strategies

8.2.5 Industrial and Transportation

8.2.5.1 Overview

8.2.5.2 Financials

8.2.5.3 Capital Expenditure

8.2.5.4 Market View

8.2.5.5 Key Strategies

8.2.6 Safety, Security and Protection Services

8.2.6.1 Overview

8.2.6.2 Financials

8.2.6.3 Capital Expenditure

8.2.6.4 Market View

8.2.6.5 Key Strategies

8.2.7 Products

8.3 Value Chain Analysis

8.3.1 Manufacturing

8.3.1.1 In House Manufacturing

8.3.2 Product Development

8.3.2.1 Regulatory Approvals

8.3.2.2 Clinical Trials

8.3.2.3 Research and Development

8.3.3 Sales and Marketing

8.3.3.1 Partnerships and Alliances

8.3.3.2 Licensing Agreements

8.3.3.3 E-distribution

8.4 SWOT Analysis

8.4.1 3M Company Strengths

8.4.1.1 Strong performance of Industrial and Transportation segment

8.4.1.2 Focused research and development

8.4.1.3 Decentralized operations

3M Company Weaknesses

8.4.1.4 Increased operating costs in the U.S.

8.4.1.5 Personal care segment’s poor performance

3M Company Opportunities

8.4.1.6 Expanding global presence

8.4.1.7 The liquid crystal display

8.4.1.8 Enhancing brand portfolio

3M Company Threats

8.4.1.9 Foreign currency fluctuations

8.4.1.10 Increasing cost of raw materials

8.4.1.11 Trend for private labels

8.5 Revenue Analysis

8.5.1 Revenue by Segment

8.5.2 Revenue by Geography

8.6 Financial and Operational Review

8.6.1 Financial Statements

8.6.2 Financial Ratios

8.7 Locations And Subsidiaries

9 Baxter International Company Profile

9.1 Company Overview

9.2 Business Overview

9.2.1 BioScience

9.2.1.1 Overview

9.2.1.2 Financials

9.2.1.3 Capital Expenditure

9.2.2 Medication Delivery

9.2.2.1 Overview

9.2.2.2 Financials

9.2.2.3 Capital Expenditure

9.2.3 Renal

9.2.3.1 Overview

9.2.3.2 Financials

9.2.3.3 Capital Expenditure

9.2.4 Products

9.2.5 History

9.3 Value Chain Analysis

9.3.1 Manufacturing

9.3.1.1 In House Manufacturing

9.3.2 Product Development

9.3.2.1 Regulatory Approvals

9.3.2.2 Clinical Trials

9.3.2.3 Research and Development

9.3.3 Sales and Marketing

9.3.3.1 Partnerships and Alliances

9.4 SWOT Analysis

9.4.1 Baxter International Inc. Strengths

9.4.1.1 Diversified geographic presence

9.4.1.2 Sturdy research and development activities

9.4.1.3 Strong financial performance

9.4.2 Baxter International Inc. Weaknesses

9.4.2.1 High levels of inventory

9.4.2.2 Decline in revenues of medication delivery

9.4.2.3 Reduced capital expenditure

9.4.3 Baxter International Inc. Opportunities

9.4.3.1 Co-developing alliances

9.4.3.2 Increasing End Stage Renal Disease patients

9.4.3.3 FDA approval

9.4.4 Baxter International Inc. Threats

9.4.4.1 Legal proceedings

9.4.4.2 Patent litigation

9.4.4.3 Stringent regulations

9.5.1 Revenue by Segment

9.5.2 Revenue by Geography

9.6.1 Financial Statements

9.6.2 Financial Ratios

9.8.1 Next-Generation Home Hemodialysis Machine

9.8.1.1 Product Overview

9.8.1.2 Product Description

9.8.1.3 Product Status

9.8.1.4 Product Milestone

10.2.1 Products

10.2.2 History

11.2.1 Major Products and Services

12.1.1 Classification of Medical Devices

12.1.2 Conformity Assessment Process

12.1.2.1 Class I devices

12.1.2.2 Class IIa devices

12.1.2.3 Class IIb devices

12.1.2.4 Class III devices

Abstract

• The report provides drug delivery devices information broken down into detailed categories and segments in Netherlands.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

• Gain a strong understanding of the drug delivery devices market in Netherlands.
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.